Mariner’s Summit Therapeutics SMMT Stock Holding History

Mariner’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-73,497	Closed	-$1.29M	–	3801
2025 Q4	$1.29M	Sell	73,497 -6,075	-8%	-$114K	﹤0.01%	1767
2025 Q3	$1.64M	Buy	79,572 +67,810	+577%	+$1.64M	﹤0.01%	1558
2025 Q2	$250K	Buy	+11,762	New	+$268K	﹤0.01%	2870

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mariner's SMMT Position: Q1 2026 in Review

Mariner sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 73,497 shares — an estimated $1.29M sold.

Mariner first reported a position in SMMT in Q2 2025 and held it in 3 quarters. The position peaked at $1.64M in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Mariner reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Mariner sold 73,497 Summit Therapeutics shares in Q1 2026, an estimated $1.29M.
Mariner first reported a position in Summit Therapeutics in Q2 2025 and held it in 3 quarters.
Mariner's Summit Therapeutics position peaked at $1.64M in Q3 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.